Hisataka Kobayashi Selected Research

Avidin

12/2011	Activatable optical imaging with a silica-rhodamine based near infrared (SiR700) fluorophore: a comparison with cyanine based dyes.
5/2010	High sensitivity detection of cancer in vivo using a dual-controlled activation fluorescent imaging probe based on H-dimer formation and pH activation.
7/2009	H-type dimer formation of fluorophores: a mechanism for activatable, in vivo optical molecular imaging.
3/2009	Fluorophore-quencher based activatable targeted optical probes for detecting in vivo cancer metastases.
1/2009	Tumor-specific detection of an optically targeted antibody combined with a quencher-conjugated neutravidin "quencher-chaser": a dual "quench and chase" strategy to improve target to nontarget ratios for molecular imaging of cancer.
11/2007	A self-quenched galactosamine-serum albumin-rhodamineX conjugate: a "smart" fluorescent molecular imaging probe synthesized with clinically applicable material for detecting peritoneal ovarian cancer metastases.
9/2007	D-galactose receptor-targeted in vivo spectral fluorescence imaging of peritoneal metastasis using galactosamin-conjugated serum albumin-rhodamine green.
9/2007	Preparation and preliminary evaluation of a biotin-targeted, lectin-targeted dendrimer-based probe for dual-modality magnetic resonance and fluorescence imaging.
4/2007	An enzymatically activated fluorescence probe for targeted tumor imaging.
3/2007	A target cell-specific activatable fluorescence probe for in vivo molecular imaging of cancer based on a self-quenched avidin-rhodamine conjugate.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hisataka Kobayashi Research Topics

Disease

184	Neoplasms (Cancer) 12/2022 - 01/2002
26	Ovarian Neoplasms (Ovarian Cancer) 01/2022 - 07/2006
20	Neoplasm Metastasis (Metastasis) 06/2022 - 09/2006
10	Breast Neoplasms (Breast Cancer) 09/2022 - 05/2004
5	Necrosis 01/2020 - 01/2002
4	Head and Neck Neoplasms (Head and Neck Cancer) 04/2022 - 01/2021
4	Stomach Neoplasms (Stomach Cancer) 01/2020 - 01/2016
4	Acute Kidney Injury (Acute Renal Failure) 01/2006 - 04/2004
3	Melanoma (Melanoma, Malignant) 01/2022 - 07/2007
3	Infections 01/2020 - 01/2017
3	Pancreatic Neoplasms (Pancreatic Cancer) 12/2019 - 07/2015
3	Urinary Bladder Neoplasms (Bladder Cancer) 01/2019 - 10/2017
3	Carcinogenesis 01/2017 - 11/2007
3	Lymphatic Metastasis 01/2016 - 05/2004
3	Ischemia 01/2006 - 07/2003
2	Carcinoma (Carcinomatosis) 06/2018 - 01/2005
2	Prostatic Neoplasms (Prostate Cancer) 01/2017 - 11/2016
2	Lung Neoplasms (Lung Cancer) 01/2017 - 01/2009
2	Lymphoma (Lymphomas) 11/2016 - 11/2005
2	Glioma (Gliomas) 01/2016 - 08/2014
2	Hepatocellular Carcinoma (Hepatoma) 06/2015 - 01/2015

Drug/Important Bio-Agent (IBA)

55	Monoclonal AntibodiesIBA 06/2022 - 02/2002
28	AntibodiesIBA 12/2022 - 05/2007
28	Coloring Agents (Dyes)IBA 12/2022 - 11/2006
22	Photosensitizing Agents (Photosensitizers)IBA 01/2021 - 11/2011
19	Contrast MediaIBA 11/2016 - 01/2002
18	phthalocyanineIBA 06/2022 - 11/2011
18	ErbB Receptors (EGF Receptor)IBA 11/2021 - 04/2007
18	Trastuzumab (Herceptin)FDA Link 01/2021 - 02/2002
17	Proteins (Proteins, Gene)FDA Link 12/2022 - 08/2008
17	AvidinIBA 12/2011 - 01/2003
16	AntigensIBA 10/2021 - 02/2002
15	Therapeutic UsesIBA 10/2021 - 09/2003
15	RhodaminesIBA 11/2018 - 11/2006
14	Pharmaceutical PreparationsIBA 01/2022 - 11/2004
12	Fluorescent Dyes (Fluorescent Probes)IBA 11/2018 - 11/2006
11	LigandsIBA 01/2022 - 07/2006
10	Galactose (Galactopyranose)FDA LinkGeneric 11/2016 - 09/2007
10	Dendrimers (Dendrons)IBA 07/2011 - 09/2003
9	Panitumumab (Vectibix)FDA Link 08/2022 - 11/2009
8	EnzymesIBA 11/2018 - 08/2013
7	Cetuximab (Erbitux)FDA Link 08/2022 - 04/2007
7	Indocyanine Green (Cardio-Green)FDA LinkGeneric 01/2021 - 02/2009
7	LuciferasesIBA 01/2020 - 07/2007
6	Immunoconjugates (Immunoconjugate)IBA 01/2020 - 07/2002
6	Red Fluorescent ProteinIBA 01/2018 - 11/2007
6	LectinsIBA 11/2016 - 07/2006
6	Indicators and Reagents (Reagents)IBA 07/2014 - 08/2008
6	GadoliniumIBA 04/2006 - 01/2003
5	Immune Checkpoint InhibitorsIBA 06/2022 - 01/2019
5	4,4- difluoro- 4- bora- 3a,4a- diaza- s- indacene (BODIPY)IBA 01/2019 - 09/2006
5	Serum AlbuminIBA 11/2016 - 09/2007
4	Neoplasm Antigens (Tumor Antigens)IBA 12/2022 - 01/2019
4	Immunoglobulin FragmentsIBA 10/2022 - 03/2011
4	Biomarkers (Surrogate Marker)IBA 06/2022 - 06/2005
4	silicon phthalocyanineIBA 10/2021 - 11/2018
4	Green Fluorescent ProteinsIBA 01/2017 - 11/2006
4	GalactosamineIBA 08/2008 - 09/2007
3	Surface Antigens (Surface Antigen)IBA 10/2022 - 06/2009
3	Biological ProductsIBA 10/2021 - 02/2011
3	Interleukin-15 (Interleukin 15)IBA 01/2021 - 01/2005
3	Immunotoxins (Immunotoxin)IBA 01/2020 - 08/2014
3	Epidermal Growth Factor (EGF)IBA 06/2018 - 11/2007
3	Immunoglobulin G (IgG)IBA 01/2017 - 04/2014
3	galactosyl serum albumin-rhodamine greenIBA 03/2014 - 11/2007
3	Growth Factor ReceptorsIBA 08/2012 - 03/2009
3	ferric oxide (iron oxide)IBA 03/2012 - 07/2011
3	Radioisotopes (Radionuclides)IBA 11/2009 - 09/2003
3	neutravidinIBA 01/2009 - 09/2006
3	Fluorescein (Funduscein)FDA LinkGeneric 09/2007 - 07/2006
2	Silicon Dioxide (Silica)FDA LinkGeneric 06/2022 - 01/2019
2	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2021 - 01/2020
2	gamma-Glutamyltransferase (gamma-Glutamyl Transpeptidase)IBA 01/2021 - 11/2016
2	Glutamic Acid (Glutamate)FDA Link 01/2021 - 11/2011
2	Fluorouracil (Carac)FDA LinkGeneric 01/2021 - 01/2016
2	AlbuminsIBA 01/2020 - 09/2017
2	ExotoxinsIBA 01/2020 - 08/2014
2	MesothelinIBA 01/2020 - 04/2016
2	human ERBB2 proteinIBA 01/2019 - 01/2017
2	GalactosidasesIBA 11/2018 - 03/2015
2	NAD (NADH)IBA 09/2017 - 01/2017
2	quinone (benzoquinone)IBA 09/2017 - 01/2017
2	IsoenzymesIBA 09/2017 - 01/2017
2	Oxidoreductases (Dehydrogenase)IBA 09/2017 - 01/2017
2	Membrane Proteins (Integral Membrane Proteins)IBA 01/2017 - 01/2009
2	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2017 - 03/2003
2	Carcinoembryonic AntigenIBA 12/2015 - 07/2015
2	GlypicansIBA 06/2015 - 01/2015
2	Human Serum Albumin FDA LinkGeneric 02/2014 - 02/2010

Therapy/Procedure

71	Therapeutics 08/2022 - 02/2004
11	Immunotherapy 12/2022 - 01/2013
9	Phototherapy (Light Therapy) 05/2021 - 01/2015
8	Drug Therapy (Chemotherapy) 09/2022 - 11/2011
7	Lasers (Laser) 04/2022 - 01/2002
4	Precision Medicine 01/2017 - 03/2012
3	Molecular Targeted Therapy 09/2022 - 03/2012
3	Quantum Dots (Quantum Dot) 01/2016 - 06/2009
3	Neutron Capture Therapy 12/2005 - 01/2003
3	Radioimmunotherapy 12/2005 - 01/2003
2	Aftercare (After-Treatment) 10/2021 - 01/2020